Shares of Crispr Therapeutics AG (NASDAQ:CRSP) have received a consensus rating of “Buy” from the eighteen research firms that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and eleven have given a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $72.86.
A number of research firms have commented on CRSP. Oppenheimer lifted their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, November 25th. Roth Capital lifted their target price on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Canaccord Genuity lifted their target price on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a report on Wednesday, November 20th. TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Finally, Chardan Capital reissued a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a report on Monday, November 18th.
CRSP stock traded down $1.22 on Monday, reaching $59.69. 994,544 shares of the company traded hands, compared to its average volume of 979,781. The company has a market cap of $3.41 billion, a P/E ratio of -17.35 and a beta of 3.31. The firm has a fifty day simple moving average of $65.80 and a 200-day simple moving average of $50.98. Crispr Therapeutics has a one year low of $27.11 and a one year high of $74.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32.
Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. On average, sell-side analysts forecast that Crispr Therapeutics will post 0.65 EPS for the current year.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the transaction, the director now directly owns 7,500 shares in the company, valued at approximately $412,500. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 56,118 shares of company stock worth $3,620,760. Company insiders own 21.40% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Crispr Therapeutics by 13.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock worth $118,000 after buying an additional 343 shares during the last quarter. Traynor Capital Management Inc. boosted its stake in shares of Crispr Therapeutics by 5.8% in the 3rd quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock worth $280,000 after buying an additional 375 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Crispr Therapeutics by 2.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock worth $746,000 after buying an additional 386 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its stake in shares of Crispr Therapeutics by 7.1% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 7,019 shares of the company’s stock worth $331,000 after buying an additional 467 shares during the last quarter. Finally, US Bancorp DE boosted its stake in shares of Crispr Therapeutics by 553.7% in the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after buying an additional 526 shares during the last quarter. Hedge funds and other institutional investors own 49.82% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: How Does the Quiet Period Work?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.